title: Compounding bevacizumab for intravitreal injection: does USP <797> always apply?
authors.affiliation: Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
authors.forename: Gary
authors.initials: G
authors.lastname: Shienbaum
authors.forename: Harry W
authors.initials: HW
authors.lastname: Flynn
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000737:chemistry*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000737:chemistry*; D000068258:Bevacizumab; D002626:Chemistry, Pharmaceutical / Q000379:methods / Q000592:standards*; D004339:Drug Compounding / Q000379:methods / Q000592:standards*; D006801:Humans; D058449:Intravitreal Injections; D010602:Pharmacopoeias as Topic / Q000592:standards*; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab